Literature DB >> 24632603

The aurora kinases in cell cycle and leukemia.

B Goldenson1, J D Crispino1.   

Abstract

The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and AURKB) and meiosis (AURKC). Since their discovery nearly 20 years ago, Aurora kinases have been studied extensively in cell and cancer biology. Several early studies found that Aurora kinases are amplified and overexpressed at the transcript and protein level in various malignancies, including several types of leukemia. These discoveries and others provided a rationale for the development of small-molecule inhibitors of Aurora kinases as leukemia therapies. The first generation of Aurora kinase inhibitors did not fare well in clinical trials, owing to poor efficacy and high toxicity. However, the creation of second-generation, highly selective Aurora kinase inhibitors has increased the enthusiasm for targeting these proteins in leukemia. This review will describe the functions of each Aurora kinase, summarize their involvement in leukemia and discuss inhibitor development and efficacy in leukemia clinical trials.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24632603      PMCID： PMC4167158          DOI： 10.1038/onc.2014.14

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  152 in total

1.  MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.

Authors:  Kara Hoar; Arijit Chakravarty; Claudia Rabino; Deborah Wysong; Douglas Bowman; Natalie Roy; Jeffrey A Ecsedy
Journal:  Mol Cell Biol       Date:  2007-04-16       Impact factor: 4.272

2.  Endomitosis of human megakaryocytes are due to abortive mitosis.

Authors:  N Vitrat; K Cohen-Solal; C Pique; J P Le Couedic; F Norol; A K Larsen; A Katz; W Vainchenker; N Debili
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

3.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Authors:  Jian-Hua Mao; Jesus Perez-Losada; Di Wu; Reyno Delrosario; Ryosuke Tsunematsu; Keiichi I Nakayama; Ken Brown; Sheila Bryson; Allan Balmain
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

4.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Authors:  Kevin R Kelly; Steffan T Nawrocki; Claudia M Espitia; Mengkun Zhang; Johnny J Yang; Swaminathan Padmanabhan; Jeffrey Ecsedy; Francis J Giles; Jennifer S Carew
Journal:  Int J Cancer       Date:  2012-06-28       Impact factor: 7.396

5.  Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice.

Authors:  Jian-Hua Mao; Di Wu; Jesus Perez-Losada; Tao Jiang; Qian Li; Richard M Neve; Joe W Gray; Wei-Wen Cai; Allan Balmain
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

6.  Degradation of human Aurora-A protein kinase is mediated by hCdh1.

Authors:  Sei ichi Taguchi; Kei Honda; Kazumitsu Sugiura; Akio Yamaguchi; Koichi Furukawa; Takeshi Urano
Journal:  FEBS Lett       Date:  2002-05-22       Impact factor: 4.124

7.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Authors:  Jaroslav Jelinek; Yasuhiro Oki; Vazganush Gharibyan; Carlos Bueso-Ramos; Josef T Prchal; Srdan Verstovsek; Miloslav Beran; Elihu Estey; Hagop M Kantarjian; Jean-Pierre J Issa
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

8.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

9.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

10.  Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis.

Authors:  R Giet; D M Glover
Journal:  J Cell Biol       Date:  2001-02-19       Impact factor: 10.539
View more
  110 in total

1.  Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells.

Authors:  Chad N Brocker; Jiang Yue; Donghwan Kim; Aijuan Qu; Jessica A Bonzo; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-01-12       Impact factor: 4.052

2.  A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP.

Authors:  Coralie Poulard; Danielle Bittencourt; Dai-Ying Wu; Yixin Hu; Daniel S Gerke; Michael R Stallcup
Journal:  EMBO Rep       Date:  2017-06-14       Impact factor: 8.807

3.  A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Authors:  S Thrane; A M Pedersen; M B H Thomsen; T Kirkegaard; B B Rasmussen; A K Duun-Henriksen; A V Lænkholm; M Bak; A E Lykkesfeldt; C W Yde
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

4.  A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.

Authors:  Paolo Strati; Loretta J Nastoupil; Richard E Davis; Luis E Fayad; Nathan Fowler; Fredrick B Hagemeister; Larry Kwak; Yasuhiro Oki; Michael Wang; Jason Westin; Charnelle E Ruben; Emily T Wesson; Richard Piekarz; Michelle A Fanale; Hun Ju Lee
Journal:  Haematologica       Date:  2019-05-09       Impact factor: 9.941

5.  Phosphorylation of MAP65-1 by Arabidopsis Aurora Kinases Is Required for Efficient Cell Cycle Progression.

Authors:  Joanna Boruc; Annika K Weimer; Virginie Stoppin-Mellet; Evelien Mylle; Ken Kosetsu; Cesyen Cedeño; Michel Jaquinod; Maria Njo; Liesbeth De Milde; Peter Tompa; Nathalie Gonzalez; Dirk Inzé; Tom Beeckman; Marylin Vantard; Daniël Van Damme
Journal:  Plant Physiol       Date:  2016-11-22       Impact factor: 8.340

6.  Aurora Kinase A is critical for the Nkx6.1 mediated β-cell proliferation pathway.

Authors:  Amanda Hobson; Carrie Draney; Andrew Stratford; Thomas C Becker; Danhong Lu; Michelle Arlotto; Jeffery S Tessem
Journal:  Islets       Date:  2015-06-01       Impact factor: 2.694

7.  Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines.

Authors:  Maryam Beigom Mobasheri; Reza Shirkoohi; Kazem Zendehdel; Issa Jahanzad; Saeid Talebi; Mandana Afsharpad; Mohammad Hossein Modarressi
Journal:  Tumour Biol       Date:  2015-05-21

8.  Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.

Authors:  M Orth; K Unger; U Schoetz; C Belka; K Lauber
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

Review 9.  Aurora B kinase: a potential drug target for cancer therapy.

Authors:  Azaj Ahmed; Anas Shamsi; Taj Mohammad; Gulam Mustafa Hasan; Asimul Islam; Md Imtaiyaz Hassan
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-28       Impact factor: 4.553

10.  Functional Analysis of the Plant Chromosomal Passenger Complex.

Authors:  Shinichiro Komaki; Hidenori Takeuchi; Yuki Hamamura; Maren Heese; Takashi Hashimoto; Arp Schnittger
Journal:  Plant Physiol       Date:  2020-05-27       Impact factor: 8.340
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.